Orris

There is a patient carcinoma prostate cT2bN0M0 high risk Gleason score 4+3=7, base line PSA 69.7 what are the treatment options and why what is the evidence for it ?

Reading File
Finding Sources
Searching PubMed

"prostate cancer" AND "high risk" AND treatment

Searching the Web

high risk prostate cancer cT2b Gleason 4+3 PSA 69 treatment guidelines 2024 2025 NCCN EAU

Reading File
Reading Article

PMID: 38614820

Reading Article

PMID: 34953525

Reading Article

PMID: 41264309

Finding Sources
Reading File
Reading File
Searching PubMed

"prostate cancer" AND "radical prostatectomy" AND "high risk" AND "radiation therapy"

Reading Article

PMID: 40683825

Reading File
Reading Web Page

https://uroweb.org/guidelines/prostate%E2%80%90cancer/chapte…

I now have comprehensive data. Let me compile the full answer.

Prostate Cancer cT2bN0M0, High-Risk, Gleason 4+3=7 (Grade Group 3), PSA 69.7 ng/mL

Risk Classification - Why This Is "High Risk"

First, let's confirm the risk category. Per NCCN 2025 and EAU 2024/2025 guidelines, high-risk prostate cancer requires at least ONE of:
  • Clinical stage T3a or above
  • Grade Group 4 or 5 (Gleason ≥8)
  • PSA >20 ng/mL
Very high-risk requires two or more of: cT3b-T4, PSA >40 ng/mL, primary Gleason pattern 5, or >4 cores GG4/5.
This patient's risk profile:
  • cT2b - bilateral disease, confined to prostate (not T3a/T3b)
  • Gleason 4+3=7 = Grade Group 3 - this is unfavorable intermediate risk by Gleason alone (GG3 does NOT qualify as high-risk by grade)
  • PSA 69.7 ng/mL = high-risk (PSA >20 ng/mL is met; note PSA >40 also met, which is a very-high-risk feature per NCCN 2025)
The PSA of 69.7 ng/mL is the dominant driver. A PSA this elevated (>40 ng/mL) with unfavorable Gleason (4+3) and bilateral disease places this patient in the high-risk / borderline very-high-risk category. NCCN 2025 lists PSA >40 ng/mL as one criterion for very-high-risk when combined with other features.
Important caveat: A PSA of 69.7 with only cT2b disease warrants restaging with PSMA PET-CT (now the standard per EAU 2024/2025) to rule out occult nodal or metastatic disease before deciding on curative intent. Conventional CT + bone scan may under-stage this patient.

Treatment Options with Evidence

Option 1: External Beam Radiotherapy (EBRT) + Long-Term ADT (± Abiraterone)

This is the preferred standard of care for high-risk non-metastatic disease.
Regimen:
  • IMRT/VMAT with image-guided RT (IGRT) to prostate (74-81 Gy or equivalent hypofractionated schedule)
  • Pelvic nodal irradiation (to common/external/internal iliac nodes) - recommended for high-risk
  • Long-term ADT for 2-3 years (GnRH agonist/antagonist)
  • Addition of abiraterone acetate + prednisolone for 2 years in patients with ≥2 high-risk features (PSA ≥40 ng/mL is one)
Evidence:
  1. STAMPEDE trial - meta-analysis (Attard et al., Lancet 2022, PMID 34953525): This landmark meta-analysis of two Phase 3 RCTs (n=1,974) showed that adding abiraterone/prednisolone to ADT + radiotherapy in high-risk non-metastatic PCa produced a metastasis-free survival HR of 0.53 (p<0.0001) and significantly improved overall survival vs ADT + RT alone. The median PSA in STAMPEDE was 34 ng/mL, making this patient directly applicable. The EAU 2025 guidelines give a Strong recommendation for abiraterone + 2-year ADT + IMRT/IGRT in patients with ≥2 high-risk features (PSA ≥40 ng/mL qualifies).
  2. ADT Duration Meta-Analysis (Zaorsky et al., JAMA Oncol 2026, PMID 41264309): Individual patient data meta-analysis of 13 Phase 3 RCTs (n=10,266) with median follow-up 11.3 years. For high-risk and very-high-risk patients, longer ADT duration had undefined optimal ceiling - benefits continued to accrue beyond 9-12 months. Standard 18-36 months ADT for high-risk is well-supported. Near-linear increase in other-cause mortality with very long ADT means 2-3 years is the sweet spot. - Harrison's Principles, 22E (2025), p.743
  3. EAU-EANM-ESTRO 2024 Guidelines (Cornford et al., Eur Urol 2024, PMID 38614820): Multi-society guideline explicitly recommends:
    • "Offer long-term ADT for at least two years" (Strong recommendation)
    • "Offer IMRT/VMAT + IGRT + long-term ADT + 2 years of abiraterone to cN0M0 patients with ≥2 high-risk factors (cT3-4, Gleason ≥8 OR PSA ≥40 ng/mL)" (Strong recommendation)
Radiation dose: 74-81 Gy conventional fractionation OR equivalent hypofractionation (e.g., 60 Gy in 20 fractions). Higher dose improves biochemical control - PSA nadir <1.0 ng/mL achieved in 90% with 81 Gy vs 56% with 64.8 Gy. - Harrison's Principles, 22E (2025)

Option 2: Radical Prostatectomy (RP) + Extended Pelvic Lymph Node Dissection (ePLND)

A valid option, particularly in younger patients, but with lower distant metastasis control in high-risk disease vs RT-based strategies.
Regimen:
  • Robot-assisted or open radical prostatectomy
  • Extended PLND (external iliac, internal iliac, obturator, and ideally common iliac nodes)
  • Adjuvant or salvage RT + ADT postoperatively if adverse pathologic features present
  • Neoadjuvant ADT alone is NOT standard (no OS benefit in trials) - Harrison's Principles, 22E (2025)
Evidence:
  1. NRG/RTOG 0521 vs CALGB 90203 (Roy et al., Eur Urol Oncol 2026, PMID 40683825): This 2026 RCT-level comparison of RT-based (n=557, RT + 24 months ADT ± docetaxel) vs RP-based (n=733, RP ± neoadjuvant docetaxel/ADT + postoperative therapy) treatment in high-risk PCa found that radiotherapy-based treatment resulted in significantly lower 8-year distant metastasis (15% vs 22%, adjusted sHR 0.58, p=0.001). Deaths after distant metastasis were equivalent. This is the most contemporary head-to-head data and suggests RT may offer superior metastasis control in high-risk disease.
  2. PSA control rates are similar between high-dose RT and contemporary surgery series. The few Phase 3 RCTs comparing RT vs RP have shown no significant oncologic differences overall, but toxicity profiles differ. - Smith & Tanagho General Urology, 19th Ed
Advantages of RP: Pathologic staging, avoidance of radiation toxicity, surgical salvage removed (instead, post-RP RT available), feasible if GU function preserved is a priority. Disadvantages: Urinary incontinence and erectile dysfunction are higher with RP than RT. - Harrison's Principles, 22E (2025)

Option 3: Combined EBRT + Brachytherapy Boost + ADT

For high-risk patients, a brachytherapy boost (HDR or LDR) added to EBRT increases the biologically effective dose and has shown improved biochemical control. - Smith & Tanagho General Urology, 19th Ed
The ASCENDE-RT trial demonstrated significantly better PSA control with a low-dose-rate brachytherapy boost vs dose-escalated EBRT in intermediate and high-risk patients. This is an option particularly if anatomically feasible.

Option 4: Docetaxel Addition (Intensified Systemic Therapy)

Per NCCN 2025 and Goldman-Cecil Medicine textbook, docetaxel can be added in patients with high-risk features, particularly:
  • Very-high-risk disease (PSA >40 ng/mL meets one criterion)
  • Part of peri-operative strategy with RP (CALGB 90203 arm used 6 cycles neoadjuvant docetaxel)
  • As intensification alongside RT + ADT in select cases
This remains less established than abiraterone addition and is typically reserved for very-high-risk or borderline metastatic presentations.

What Is NOT Recommended

  • Active surveillance: Absolutely inappropriate. PSA 69.7 and Gleason 4+3 preclude this.
  • ADT monotherapy alone: Only for patients unfit for local treatment or palliative intent. Inferior to combined modality therapy for potential cure.
  • Neoadjuvant ADT before RP: Multiple large trials show no improvement in clinically relevant outcomes; not standard of care. - Harrison's Principles, 22E (2025)
  • Whole gland focal therapy (HIFU, cryotherapy): EAU 2025 states "Do not offer whole gland treatment or focal treatment" for high-risk disease (Strong recommendation).

Restaging Before Definitive Treatment

Given PSA 69.7 ng/mL with cT2b:
  • PSMA PET-CT is mandatory (EAU 2024/2025: Strong recommendation). This PSA level substantially raises the probability of nodal or occult metastatic disease that conventional CT + bone scan will miss. If PSMA PET-CT unavailable, do CT abdomen/pelvis + bone scan.
  • If N1 on PSMA PET-CT: Treatment intensifies - IMRT to prostate + pelvis + long-term ADT + 2-year abiraterone (EAU 2025 Strong recommendation).
  • If M1 (oligometastatic): Different pathway - hormone-sensitive metastatic disease protocols apply (ADT + novel hormonal agents ± docetaxel).

Summary Table

OptionEvidence GradeKey Trial(s)Notes
EBRT + 2-3yr ADT + abiraterone 2yrStrong (EAU/NCCN)STAMPEDE (Lancet 2022)Preferred for ≥2 high-risk features; PSA 69.7 qualifies
EBRT + 2-3yr ADT (without abiraterone)StrongMultiple Phase 3 RCTsIf abiraterone not tolerated/available
Radical prostatectomy + ePLNDModerateNRG/CALGB 2026 RCT dataValid; higher DM risk vs RT in high-risk; preferred in younger patients
EBRT + brachytherapy boost + ADTModerateASCENDE-RTDose escalation option
Docetaxel additionWeak-ModerateNRG 0521 (RP arm)Very-high-risk/borderline patients

Clinical Bottom Line for This Patient

This patient has PSA 69.7 with one definitive high-risk criterion (PSA >20 ng/mL) and one NCCN very-high-risk feature (PSA >40 ng/mL). Assuming PSMA PET-CT confirms cN0M0:
Recommended approach (EAU 2025 Strong recommendation):
IMRT/VMAT + IGRT to prostate and pelvis + 2-3 years of ADT (GnRH agonist/antagonist) + abiraterone acetate/prednisolone for 2 years
This is based directly on STAMPEDE and aligns with both EAU 2024/2025 and NCCN 2025 guidelines. Surgery remains an alternative in fit/younger patients but the 2026 RCT data (Roy et al.) supports RT-based strategies as having lower distant metastasis rates in high-risk disease.
Key references:
This is a shared conversation. Sign in to Orris to start your own chat.